P17.35 GEINO-10: A PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY OF THE CHARACTERISTICS OF PATIENTS WITH INTRA-AXIAL BRAIN TUMOURS AND THEIR THERAPEUTIC MANAGEMENT IN SPANISH HOSPITALS

Documenti analoghi

• ATCT-05 OBJECTIVE RESPONSE (OR) TO NEOADJUVANT TREATMENT IN GLIOBLASTOMA AND ITS IMPACT ON OVERALL SURVIVAL (OS). A META-ANALYSIS OF NEOADJUVANT TRIALS OF THE SPANISH GROUP FOR RESEARCH IN NEUROONCOLOGY (GEINO)
  di: Balana, Carmen, et al.
  Pubblicazione: (2015)
• P17.04 RANO CRITERIA APPLIED TO A PHASE II RANDOMIZED, MULTICENTER TRIAL COMPARING TEMOZOLOMIDE (TMZ) VS TMZ-PLUS-BEVACIZUMAB (BEV) BEFORE STANDARD TREATMENT IN UNRESECTABLE GLIOBLASTOMA (GBM) PATIENTS (P).GENOM 009 STUDY BY THE GEINO GROUP
  di: Balaña, C., et al.
  Pubblicazione: (2014)
• P14.58 Extending adjuvant temozolomide longer than six cycles doesn’t add any benefit to glioblastoma patients according to the randomized GEINO-014 TRIAL
  di: Balana, C, et al.
  Pubblicazione: (2019)
• ACTR-48. AN APPRAISAL OF THE IMPACT ON SURVIVAL OF NEOADJUVANT TREATMENTS DELAYING RADIOTHERAPY IN ‘ONLY-BIOPSIED GLIOBLASTOMA’ TRIALS CONDUCTED BY THE GEINO GROUP COMPARED TO PATIENTS TREATED WITH THE STUPP’S REGIME. EXPERIENCE OF THE GEINO AND THE GLIOCAT GROUP
  di: Balana, Carme, et al.
  Pubblicazione: (2017)
• A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
  di: Balana, Carmen, et al.
  Pubblicazione: (2020)